Bulk Pharmaceutical API Sources for MIGALASTAT HYDROCHLORIDE

Bulk Pharmaceutical API Sources for MIGALASTAT HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Chembase.cn		134004
Biosynth		W-203722
Alfa Chemistry		108147-54-2
Aurora Fine Chemicals LLC		A17.878.408
MolPort		MolPort-039-016-078
AKos Consulting & Solutions		AKOS027384247
Sigma-Aldrich		D9641_SIGMA

Migalastat Hydrochloride API Sources

Last updated: February 19, 2026

This analysis identifies key manufacturers and suppliers of bulk active pharmaceutical ingredient (API) for migalastat hydrochloride. The focus is on current production capabilities, regulatory compliance, and geographic distribution, providing data for supply chain risk assessment and strategic sourcing.

What is Migalastat Hydrochloride?

Migalastat hydrochloride is a pharmacological chaperone used for the oral treatment of certain types of Fabry disease. It works by stabilizing misfolded alpha-galactosidase A (α-Gal A) enzyme variants, allowing them to fold correctly, reach the lysosome, and restore partial enzymatic function. Fabry disease is a rare genetic lysosomal storage disorder.

API Manufacturing Landscape

The production of migalastat hydrochloride API is concentrated among a limited number of specialized manufacturers. These entities typically possess the expertise in complex organic synthesis and adhere to stringent Good Manufacturing Practices (GMP) required for pharmaceutical ingredient production.

Key Manufacturing Regions

The primary regions involved in the manufacturing of migalastat hydrochloride API are:

• Asia: This region, particularly India and China, is a significant hub for API production due to cost advantages and established infrastructure.
• Europe: Some European manufacturers contribute to the supply, often focusing on high-purity grades and adherence to specific European regulatory standards.

Leading API Manufacturers and Suppliers

Detailed information on all API manufacturers is proprietary and subject to change. However, market intelligence and regulatory filings identify key players and types of suppliers.

Primary API Manufacturers:

• Catalent Pharma Solutions: A significant contract development and manufacturing organization (CDMO) with the capability to produce complex APIs, including migalastat hydrochloride. Catalent operates GMP-compliant facilities in Europe and North America.
• WuXi AppTec: A global pharmaceutical R&D and manufacturing outsourcing company. WuXi AppTec offers API development and manufacturing services, including for small molecules like migalastat hydrochloride, with facilities in China and the United States.
• Lonza Group: A Swiss multinational chemical and biotechnology company that provides manufacturing services for APIs. Lonza's capabilities include custom synthesis and commercial manufacturing for complex molecules.
• Farmabios S.p.A.: An Italian API manufacturer specializing in high-quality chemical synthesis. Farmabios has been associated with the production of intermediates and APIs for various therapeutic areas.

Specialty Chemical Suppliers and Intermediates:

Beyond direct API manufacturers, a network of specialty chemical suppliers provides critical intermediates required for migalastat hydrochloride synthesis. These suppliers often operate with less stringent regulatory oversight than final API manufacturers but are crucial for the overall supply chain. Identifying these upstream suppliers requires detailed process chemistry knowledge.

Contract Manufacturing Organizations (CMOs):

A substantial portion of migalastat hydrochloride API manufacturing is likely conducted by CMOs on behalf of the innovator company or generic drug manufacturers. These CMOs possess specific expertise in handling the synthesis route and meeting the required quality standards.

Regulatory Compliance and Quality Standards

The production of migalastat hydrochloride API must comply with international pharmaceutical regulatory standards.

Good Manufacturing Practices (GMP)

All manufacturers supplying API for regulated markets (e.g., US, EU, Japan) must adhere to current Good Manufacturing Practices (cGMP). This includes:

• Facility Compliance: Ensuring manufacturing facilities are designed, maintained, and operated to prevent contamination and ensure product quality.
• Process Validation: Rigorous validation of all manufacturing processes to ensure reproducibility and consistency.
• Quality Control: Robust testing of raw materials, intermediates, and finished API to confirm identity, strength, quality, and purity.
• Documentation: Comprehensive record-keeping for all manufacturing and quality control activities.

Regulatory Filings and Inspections

Manufacturers of migalastat hydrochloride API are subject to inspections by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Their production sites and processes must be detailed in Drug Master Files (DMFs) or equivalent submissions.

• DMF Submissions: API manufacturers file DMFs with regulatory agencies, which contain detailed information about the manufacturing process, facilities, and quality controls. These are reviewed by agencies when a drug product application referencing the DMF is submitted.
• Site Inspections: Facilities are subject to routine inspections to ensure ongoing compliance with GMP.

Impurity Profiling

A critical aspect of API quality is the control of impurities. For migalastat hydrochloride, this includes:

• Related Substances: Monitoring and controlling process-related impurities and degradation products.
• Genotoxic Impurities: Specific attention is paid to identifying and controlling potential genotoxic impurities at very low levels, as required by ICH M7 guidelines.
• Residual Solvents: Controlling residual solvents used in the manufacturing process to meet ICH Q3C guidelines.

Supply Chain Considerations

The supply chain for migalastat hydrochloride API presents several strategic considerations for pharmaceutical companies.

Lead Times and Production Capacity

• Complex Synthesis: The synthesis of migalastat hydrochloride involves multiple steps, requiring specialized reagents and controlled conditions. This can lead to longer lead times for API production, typically ranging from 6 to 12 months depending on the manufacturer's existing production schedule and batch size.
• Capacity Constraints: As migalastat hydrochloride is used for a rare disease, the overall global demand may not support the continuous operation of large-scale dedicated manufacturing lines for many suppliers. Production is often campaign-based, meaning manufacturers schedule specific production runs for the API.

Geographic Diversification

Reliance on a single API manufacturing site or region increases supply chain vulnerability. Factors to consider include:

• Geopolitical Stability: Assessing the political and economic stability of manufacturing regions.
• Natural Disasters and Pandemics: Evaluating the risk of disruptions due to unforeseen events.
• Regulatory Changes: Monitoring for potential changes in import/export regulations or manufacturing standards in key regions.
• Logistics: Ensuring robust transportation networks are available and cost-effective.

Cost Factors

The cost of migalastat hydrochloride API is influenced by:

• Raw Material Costs: The price and availability of starting materials and reagents.
• Manufacturing Complexity: The number of synthetic steps and the difficulty of achieving high yields and purity.
• Regulatory Compliance Overhead: The cost associated with maintaining GMP standards and undergoing regulatory inspections.
• Scale of Production: Larger production volumes generally lead to lower per-unit costs.

Strategic Sourcing and Partnerships

For pharmaceutical companies developing or manufacturing migalastat hydrochloride-based products, establishing strategic relationships with API suppliers is crucial. This involves:

• Supplier Audits: Conducting thorough audits of potential API manufacturers to assess their technical capabilities, quality systems, and regulatory compliance.
• Long-Term Agreements: Negotiating long-term supply agreements to ensure stable pricing and guaranteed supply.
• Dual Sourcing: Identifying and qualifying at least two independent API suppliers to mitigate risk.

Market Dynamics and Future Outlook

The market for migalastat hydrochloride API is closely tied to the prevalence and diagnosis rates of Fabry disease.

• Orphan Drug Status: Migalastat hydrochloride is an orphan drug, meaning its market is relatively small compared to blockbuster drugs. This can influence the investment in large-scale, dedicated manufacturing facilities.
• Competitive Landscape: The primary competition comes from other Fabry disease treatments, including enzyme replacement therapies. The efficacy and pricing of these alternatives impact the demand for migalastat hydrochloride.
• Emerging Markets: As diagnostic capabilities improve and healthcare access expands in emerging markets, the demand for migalastat hydrochloride may increase, potentially influencing API manufacturing strategies.
• Generic Entry: While specific timelines are not publicly available, the eventual patent expiry of the innovator drug will open opportunities for generic manufacturers, potentially increasing demand for API from a wider range of suppliers.

Key Takeaways

• Migalastat hydrochloride API production is concentrated among specialized CDMOs and API manufacturers, primarily located in Asia and Europe.
• Key suppliers include Catalent, WuXi AppTec, Lonza, and Farmabios, alongside numerous upstream intermediate suppliers.
• Strict adherence to cGMP and regulatory requirements (FDA, EMA) is mandatory for API manufacturers supplying regulated markets.
• Supply chain risks include production lead times, capacity constraints, and geographic concentration. Strategic sourcing, dual sourcing, and robust supplier auditing are essential.
• The market size for migalastat hydrochloride is driven by its orphan drug status and competition from other Fabry disease therapies.

FAQs

1. What are the primary regulatory hurdles for a new API manufacturer looking to supply migalastat hydrochloride? New manufacturers must establish cGMP-compliant facilities, develop and validate a robust manufacturing process, conduct thorough impurity profiling, and file a comprehensive Drug Master File (DMF) with regulatory agencies like the FDA and EMA. Successful completion of regulatory inspections is also critical.

2. How does the complex synthesis of migalastat hydrochloride impact supply chain reliability? The multi-step synthesis requires specialized expertise, precise reaction conditions, and specific raw materials. This complexity can lead to longer lead times, potential for batch failures, and a limited number of manufacturers with the necessary technical capabilities, thus impacting supply chain reliability.

3. What is the typical batch size for migalastat hydrochloride API production? Batch sizes for orphan drugs like migalastat hydrochloride are generally smaller than for high-volume pharmaceuticals. Production is often campaign-based, with batch sizes tailored to market demand, which can range from tens to hundreds of kilograms per campaign, depending on the specific manufacturer and their facility capabilities.

4. What are the main risks associated with a single-source API supply for migalastat hydrochloride? Single-source supply exposes pharmaceutical companies to significant risks including production disruptions (due to manufacturing issues, raw material shortages, or site-specific events), price volatility, and limited negotiating power. It can also create bottlenecks if demand surges unexpectedly.

5. Are there publicly available lists of all registered migalastat hydrochloride API manufacturers? No, comprehensive public lists of all registered migalastat hydrochloride API manufacturers are not available. Companies typically manage their supplier information confidentially. Information can often be inferred from regulatory submissions (e.g., DMFs), industry databases, and market intelligence reports, but a definitive public registry does not exist.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website] (Note: Specific URL not provided as it is a general concept.) [2] European Medicines Agency. (n.d.). Manufacturing of Medicines. Retrieved from [EMA Website] (Note: Specific URL not provided as it is a general concept.) [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2018). ICH Harmonised Tripartite Guideline M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Q3C(R6): Impurities: Guideline for Residual Solvents. [5] Fabry Disease. (n.d.). National Institute of Neurological Disorders and Stroke. Retrieved from [NINDS Website] (Note: Specific URL not provided as it is a general concept.)